Day: February 11, 2022

Remarks by Dr. Shmuel Yitzhaki, as published in Globes, an Israeli business newspaper BriLife vaccine may have better neurtralizing ability against Omicron variant than first generation mRNA vaccines, according to IIBR findingsRADNOR, Pa., Feb. 11, 2022 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (Nasdaq: NRXP), a clinical-stage, biopharmaceutical company, today reported remarks by Dr. Shmuel Yitzhaki, Director of the Israel Institute for Biological Research, who spoke at the Eli Hurvitz Institute for Strategic Management of Tel Aviv University. His remarks were summarized in the Hebrew language edition of Globes as follows: Dr. Shmuel Yitzhaki, the Director of the Israeli Institute for Biological Research, shared in a conference, the story of the development of the Israeli vaccine for Covid, which is in clinical trials these days,...

U.S. FDA clears IND to evaluate MET642 for the treatment of ulcerative colitis Sufficient capital to complete Phase 2 IBD trialSAN DIEGO, Feb. 11, 2022 (GLOBE NEWSWIRE) — Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with gastrointestinal and liver diseases, today announced that it remains on track to begin a Phase 2 clinical trial in ulcerative colitis. Metacrine has received authorization from the U.S. Food and Drug Administration (FDA) to proceed with its Phase 2 trial evaluating MET642 in subjects with inflammatory bowel disease (IBD) and expects to begin the study in the first half of 2022. To support ongoing clinical development of MET642 in IBD, the Company is implementing a restructuring plan to significantly reduce expenses associated with...

ST. JOHN’S, Newfoundland and Labrador, Feb. 11, 2022 (GLOBE NEWSWIRE) — Fortis Inc. (“Fortis” or the “Corporation”) (TSX/NYSE: FTS) today filed its audited Consolidated Financial Statements and related Management Discussion and Analysis for the year ended December 31, 2021, as well as its 2021 Annual Information Form, with Canadian securities regulatory authorities. The Corporation has also filed its Form 40-F for the year ended December 31, 2021 with the U.S. Securities and Exchange Commission. Copies of these documents are available electronically at www.sedar.com (Canadian filings), www.sec.gov (U.S. filings) and the Corporation’s website, www.fortisinc.com, or by emailing investorrelations@fortisinc.com. The Management Information Circular for the Corporation’s upcoming Annual and Special...

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of inducement awards outside of the Company’s 2019 Stock Incentive Plan to Amy Winnen, the Company’s newly appointed Vice President, Head of Market Value, Access and Policy. The grant was approved by a majority of the independent directors of the Company on February 3, 2022 as an inducement material to the employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consisted of a nonstatutory option to purchase up to 43,260 shares of common stock. The option has an exercise price of $10.93 per share, the closing price per share...

CHICAGO, Feb. 11, 2022 (GLOBE NEWSWIRE) — GCM Grosvenor (Nasdaq: GCMG), a global alternative asset management solutions provider, announced today that it raised $1.5 billion for diverse manager investment mandates in 2021, bringing its total diverse manager assets under management (AUM) to approximately $11 billion as of December 31, 2021. The $1.5 billion consists of approximately $500 million raised for diverse manager mandates in Real Estate and $1.0 billion raised for diverse manager mandates in Private Equity, including capital raised for the firm’s $770 million inaugural Advance Fund, which held its final closing on December 30, 2021. A total of 55 institutional investors made commitments to diverse manager mandates in 2021, 43 of which were new investors to GCM Grosvenor. GCM Grosvenor has invested with diverse managers...

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) — Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference. 11th Annual SVB Leerink Global Healthcare Conference Date: Friday, February 18, 2022Time: 2:20 PM ET A live webcast of the presentation will be available via the Investors section of the Company’s website at www.vorbio.com. An archived replay of the webcast will also be available following the conference. About Vor BiopharmaVor Biopharma is a clinical-stage cell and genome engineering company that aims to change the standard of care for patients with blood cancers by engineering hematopoietic stem cells to enable targeted therapies...

WOBURN, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced that Philip Astley-Sparke, Chief Executive Officer of Replimune, will present in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference being held virtually on Friday, February 18, 2022 at 8:40 AM ET. A simultaneous webcast will be available in the Investors section of Replimune’s website at www.replimune.com. A replay will be available for approximately 90 days following the conference. About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic...

SCOTTSDALE, Ariz., Feb. 11, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that it received notice from its exclusive licensing partner in Japan, Maruho Co., Ltd. (“Maruho”), that Japan’s Ministry of Health, Labor and Welfare (“MHLW”) approved Rapifort® Wipes 2.5% (glycopyrronium tosylate hydrate) for the treatment of primary axillary hyperhidrosis. This approval triggers a milestone payment of $10 million to Journey Medical, $7.5 million of which will be paid to Dermira, Inc. (“Dermira”), a wholly-owned subsidiary of Eli Lilly and Company, pursuant to the terms of the Asset Purchase Agreement between...

FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23rd, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook. Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com About Cytek BiosciencesCytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™...

VANCOUVER, Wash., Feb. 11, 2022 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced the company will be participating virtually in the upcoming BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. Absci’s management is scheduled to present on Tuesday, February 15th at 8:30 a.m. Pacific Time / 11:30 a.m. Eastern Time. To listen to the live event, please contact your BTIG representative with interest. About Absci Absci is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. We built our Integrated Drug Creation™ Platform to identify novel drug targets, discover optimal biotherapeutic...